Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

NEW YORK--(BUSINESS WIRE)--May 15, 2007 - SIGA Technologies, Inc. (NASDAQ: SIGA) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193.

This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule."

"This is a tremendous milestone for our research group," said Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer. "This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future."

Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenav
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:6/30/2015)... Legal-Bay LLC, the Lawsuit Settlement Funding Company, ... multidistrict litigation (MDL) over the Zimmer NexGen Knee implant ... , 2015. There are currently more than a thousand ... a federal judge in Illinois . ... begin in October of this year. Zimmer Inc. previously ...
(Date:6/29/2015)... -- , Gerresheimer will sell its borosilicate glass ... into a 10-year-supply agreement for pharmaceutical glass tubing ... Corning and Gerresheimer will form a joint ... Gerresheimer,s outlook for the financial years 2016 to ... tubing business , In line with its strategy ...
(Date:6/29/2015)... 29, 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ... credit agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby ... of secured debt financing. CareView is an information technology ... monitoring. Under the credit agreement, PDL will ... financing in two tranches of $20 million, based upon ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 2Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4
(Date:6/30/2015)... ... 30, 2015 , ... The board certified otolaryngologists at Clear ... to inform potential sinus surgery patients about ear, nose, and throat (ENT) ailments ... a wide variety of ENT issues including hearing loss, ear infections, dizziness, sleep ...
(Date:6/30/2015)... ... June 30, 2015 , ... Villa Health Care ... centers in the country. To spread the word, Villa Health Care Center created ... is, indeed, worthy of five stars. While Medicare centers its rating on health ...
(Date:6/30/2015)... ... 2015 , ... The LIV Fertility Center in Puerto Vallarta is ... age to pursue egg freezing. Statistics show that 20 percent of women are waiting ... percent increase since the 1970s. , Sadly, for women who have delayed parenthood for ...
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, 2015 , ... ... Reasons You Have Acne ,” listed five triggers that most people would not ... cloths, hair care products, and toothpaste. The primary causes of acne are ...
Breaking Medicine News(10 mins):Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:Villa Health Care Center Announces Highest Care Rating in New Video 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2
... A recently published study revealed that virological breakthrough (VBT) ... chronic hepatitis B. Nearly 40% of the VBTs found ... this retrospective study are published in the May issue ... on behalf of the American Association for the Study ...
... drug memantine submitted a supplementary analysis of study data, the ... sees proof of a benefit of the drug for cognitive ... of daily living, at least for a treatment period of ... benefit assessment of 2009. IQWiG had repeatedly called upon the ...
... Goodwin HealthDay Reporter , TUESDAY, April 26 (HealthDay ... attacks, such as clot-busting drugs and rapid angioplasty, has led ... Researchers used data from a Swedish coronary care registry ... type of deadly heart attack known as STEMI between 1996 ...
... for publication in The Endocrine Society,s Journal of Clinical ... white children with vitamin D deficiency both had higher fat ... of fat just under their skin and white children were ... internal organs. Studies in adults and children have shown ...
... , TUESDAY, April 26 (HealthDay News) -- Seniors who ... of developing Alzheimer,s disease, a new study suggests. ... house causes dementia, and other factors could explain the ... cost of isolation, said lead investigator Bryan D. James, ...
... University bioengineering students in collaboration with the Texas Heart ... to arrhythmia victims headed toward cardiac arrest. For ... created a unique pad system for automated external defibrillators ... back into a proper rhythm in an emergency. ...
Cached Medicine News:Health News:Hepatitis B virus reemerges with long-term nucleoside analog treatment 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 3Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 2Health News:Being 'Housebound' Linked to Alzheimer's in Elderly 3Health News:Unique AED pads give hearts a second chance 2
For the quantitative determination of uric acid in serum....
For determination of uric acid in serum, plasma or urine. For Hitachi 704 / 911. Available with Calibrator: Trucal U and controls: Trulab N and Trulab P....
For the quantitative determination of uric acid in serum....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
Medicine Products: